Tempus AI CFO James Rogers Cashes In $2.7M Worth of Shares—Here’s What It Means for Investors
Tempus AI (NASDAQ: TEM) Chief Financial Officer James William Rogers sold 48,842 shares of Class A Common Stock on August 18 and August 19, 2026, according to a recent SEC Form 4 filing. The transactions, executed at a weighted-average price of $55.21 per share, were valued at roughly $2.7 million.
Transaction Summary
- Transaction value: $2.7 million
- Shares sold (direct): 48,842
- Post-transaction shares (directly held): 106,024
- Post-transaction value: $6.49 million
Transaction value based on SEC Form 4 weighted average sale price ($55.21); post-transaction value based on the August 19 market close ($61.25).
Key Takeaways for Investors
What was the primary driver of this transaction?
The disposition was a non-discretionary sell-to-cover event intended to satisfy statutory tax withholding requirements upon the vesting of restricted stock units (RSUs). The activity was conducted under a Rule 10b5-1 trading plan adopted on September 11, 2025, and does not reflect a change in the insider’s fundamental outlook on the company.
How much direct equity does the CFO retain?
Following this sale, James William Rogers retains direct ownership of 106,000 shares of Class A Common Stock. This position represents an insider ownership stake of roughly 0.06% of the company’s outstanding equity.
What is the recent performance context for the stock?
As of the August 19 transaction date, the one-year total return for the stock was -16%. The transaction was executed at a weighted-average price of $55.21 per share, while the stock finished the August 19 session at $61.25.
What is the company’s current financial profile?
Tempus AI, based in Chicago, operates in the healthcare information services industry with approximately 3,800 employees. The company reported trailing twelve-month (TTM) revenue of $1.4 billion and a net loss of $254.4 million, maintaining a total market capitalization of $10.7 billion.
Company Overview
- Share Price (as of market close 2026-08-19): $61.25
- Market Capitalization: $10.7 billion
- Revenue (TTM): $1.4 billion
- Net Income (TTM): -$254.4 million
Why This Matters
Rogers’s sale follows the same 10b5-1 plan structure adopted in September 2025. Like similar filings from Tempus AI’s diagnostics, data, and accounting chiefs in recent days, this transaction split across August 18 and August 19, catching shares on both sides of the Moderna and Merck trial news that sent Tempus stock up 24% in a single session.
Despite ongoing net losses, Tempus AI recently delivered its first GAAP profit, posting $5.6 million in net income for the second quarter—bolstered by $98.5 million in unrealized gains on marketable securities—and saw revenue climb 22% to $382.5 million. Management raised full-year guidance to $1.6 billion and closed a $460 million convertible note offering during the quarter, building a balance sheet strong enough to fund a $1.5 billion acquisition without straining cash.
Tempus AI operates a closed-loop, full-stack healthcare technology platform that integrates clinician workflows with laboratory diagnostic capabilities, analytics, and multimodal data repositories, generating revenue primarily through diagnostic testing services and platform licensing.
Frequently Asked Questions (FAQ)
1. Is the Tempus AI CFO selling his shares a red flag?
Not necessarily. This transaction was a non-discretionary sell-to-cover event to pay taxes on vested RSUs, executed under a Rule 10b5-1 trading plan adopted in September 2025. Such pre-scheduled sales are common among executives and don’t typically signal a change in outlook.
2. How much of Tempus AI does James Rogers still own after this sale?
Rogers retains approximately 106,024 shares of Class A Common Stock directly, representing about 0.06% of the company’s outstanding equity. At the August 19 closing price of $61.25, this stake is valued at roughly $6.49 million.
3. How has Tempus AI stock performed recently?
TEM had a one-year total return of -16% as of August 19, 2026. However, the stock jumped 24% in a single session following Moderna and Merck trial news, showing significant volatility tied to clinical and industry catalysts.
